241 related articles for article (PubMed ID: 27388147)
1. Improving testing for hepatitis B before treatment with rituximab.
Dyson JK; Jopson L; Ng S; Lowery M; Harwood J; Waugh S; Valappil M; McPherson S
Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1172-8. PubMed ID: 27388147
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
Chen YM; Chen HH; Huang WN; Chen YH; Hsieh TY; Yang SS; Lan JL; Chen DY
Int J Rheum Dis; 2019 Jun; 22(6):1145-1151. PubMed ID: 31117160
[TBL] [Abstract][Full Text] [Related]
5. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
[TBL] [Abstract][Full Text] [Related]
6. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
7. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
Tien YC; Yen HH; Chiu YM
Clin Exp Rheumatol; 2017; 35(5):831-836. PubMed ID: 28375829
[TBL] [Abstract][Full Text] [Related]
8. Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation.
Ohkubo M; Seo E; Doki K; Suzuki Y; Sekine I; Homma M
Biol Pharm Bull; 2024; 47(5):941-945. PubMed ID: 38735754
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
10. Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study.
Notsumata K; Nomura Y; Tanaka A; Nomura Y; Ueda T; Sanada T; Watanabe H; Toya D
Intern Med; 2020; 59(20):2457-2464. PubMed ID: 33055468
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B screening before rituximab therapy: a multicentre South Australian study of adherence.
Hall SAL; Shaikh A; Teh K; Tantiongco M; Coghlan D; Karapetis CS; Chinnaratha MA; Woodman R; Muller KR; Wigg AJ
Intern Med J; 2018 Aug; 48(8):936-943. PubMed ID: 29345413
[TBL] [Abstract][Full Text] [Related]
12. Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation.
Lee J; Park JY; Kim DG; Lee JY; Kim BS; Kim MS; Il Kim S; Kim YS; Huh KH
Sci Rep; 2018 Oct; 8(1):15629. PubMed ID: 30353021
[TBL] [Abstract][Full Text] [Related]
13. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience.
Oh MJ; Lee HJ
Clin Mol Hepatol; 2013 Mar; 19(1):51-9. PubMed ID: 23593610
[TBL] [Abstract][Full Text] [Related]
14. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study.
Wang Y; Luo XM; Yang D; Zhang J; Zhuo HY; Zhang J; Jiang Y
World J Gastroenterol; 2013 Feb; 19(6):923-30. PubMed ID: 23429298
[TBL] [Abstract][Full Text] [Related]
15. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
Tang Z; Li X; Wu S; Liu Y; Qiao Y; Xu D; Li J
Hepatol Int; 2017 Sep; 11(5):429-433. PubMed ID: 28856548
[TBL] [Abstract][Full Text] [Related]
16. Short article: Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases.
Spinicci M; Emmi G; Dies L; Barilaro A; Vitiello G; Mencarini J; Cavallo A; Bartoloni A; Bartalesi F
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):756-760. PubMed ID: 29649073
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
18. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
[TBL] [Abstract][Full Text] [Related]
19. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients.
Lee J; Park JY; Huh KH; Kim BS; Kim MS; Kim SI; Ahn SH; Kim YS
Nephrol Dial Transplant; 2017 Apr; 32(4):722-729. PubMed ID: 28339910
[TBL] [Abstract][Full Text] [Related]
20. Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience.
Junus K; Aguilar M; Patel P; Irwin D; Yee S; Liu B; Bhuket T; Wong RJ
Cancer; 2017 Feb; 123(4):650-656. PubMed ID: 27696389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
